Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
Sundar Jagannath
Consultant or Advisory Role - Celgene; Merck Sharp & Dohme; Millennium; Onyx
Honoraria - Celgene; Merck Sharp & Dohme; Millennium; Onyx
Craig C. Hofmeister
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Merck; Millennium; Oncolytics Biotech
Rachid C. Baz
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Sanofi
David Samuel DiCapua Siegel
Honoraria - Celgene; Merck; Millennium; Onyx
Ravi Vij
Consultant or Advisory Role - Celgene; Onyx
Honoraria - Celgene; Millennium; Onyx
Research Funding - Celgene; Onyx
Christine Chen
Honoraria - Celgene
Research Funding - Celgene
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi
Kenneth Carl Anderson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Onyx
Other Remuneration - Acetylon Pharmaceuticals; OncoPep
Min Chen
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Mohamed H. Zaki
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Paul Gerard Guy Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium